AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11325685
Drug: Intravenous L-carnitine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-carnitine, 20 mg/kg
Trial: 11325685
Drug: Intravenous L-carnitine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-carnitine, 10 mg/kg
Trial: 11325685
Drug: Intravenous L-carnitine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-carnitine, 40 mg/kg
Trial: 2122016
Drug: Intravenous L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-carnitine
Trial: 9621293
Drug: Mupirocin ointment
RxNorm normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin ointment applied at the cannula site after catheter placement and at the end of each dialysis session
Trial: 2363109
Drug: Lidocaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (20 mg/ml) with epinephrine (12.5 micrograms/ml)
Trial: 2363109
Drug: Prilocaine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine (30 mg/ml) with felypressin (0.54 microgram/ml)
Trial: 2363109
Drug: Mepivacaine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine (30 mg/ml)
Trial: 21508826
Drug: S-ketamine 20
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine 20 mg/70 kg/h with rifampicin (600 mg once daily for 5 days)
Trial: 21508826
Drug: S-ketamine 40
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine 40 mg/70 kg/h with rifampicin (600 mg once daily for 5 days)
Trial: 15593207
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous cyclophosphamide (IV CYC) regimen (6 pulses of 500 mg given at intervals of 2 weeks) followed by azathioprine (AZA)
Trial: 15593207
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous cyclophosphamide (IV CYC) regimen (6 monthly pulses and 2 quarterly pulses with escalating doses) followed by azathioprine (AZA)
Trial: 15593207
Drug: Early response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early response to therapy (defined as a decrease in serum creatinine level and proteinuria <1 g/24 hours)
Trial: 8333773
Drug: Intermittent growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent growth hormone treatment (three weeks of every four)
Trial: 8333773
Drug: Continuous growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous growth hormone treatment (daily injection)
Trial: 26225500
Drug: QLB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLB with 0.125% bupivacaine 0.2 ml kg⁻¹ (Group 1)
Trial: 26225500
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (QLB with 0.9% Normal saline 0.2 ml kg⁻¹)
Trial: 24190233
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (EPA 1245 mg/day, DHA 540 mg/day)
Trial: 18706028
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (GTN, 5 mg/day)
Trial: 8576660
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA (Patient-Controlled Analgesia)
Trial: 8576671
Drug: Conventional method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional method (Intramuscular q.i.d. injection and p.r.n. injection)
Trial: 2354091
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml of plain 0.5% bupivacaine injected at L3-4
Trial: 2354091
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml of plain 0.5% bupivacaine injected at L4-5
Trial: 29171020
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg on day 1 and 75 mg on day 2)
Trial: 29171020
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg on day 1 and 10 mg on day 2)
Trial: 20134306
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (triamcinolone acetonide)
Trial: 22721455
Drug: NSAID injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID injection (diclofenac sodium)
Trial: 19672733
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - oral 0.625 mg conjugated estrogen + 2.5 mg medroxyprogesterone acetate/day for 3 and 6 months
Trial: 17377770
Drug: Intravenous fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fish oil fat emulsion (0.5 g/kg 10% emulsion, Omegaven) administered twice, 48 and 24 hours before investigation.
Trial: 14977388
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 microg daily
Trial: 16276692
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate 400 microg twice daily
Trial: 14618035
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug therapy (amiodarone, propafenone, flecainide, sotalol)
Trial: 16698176
Drug: Propiverine 15
RxNorm normalized name: propiverine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine 15 mg t.i.d.
Trial: 7606516
Drug: Nedocromil sodium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium, 4 mg aerosol 30 min before challenge
Trial: 2206227
Drug: Triple drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple drug treatment (azathioprine, cyclosporin, methylprednisolone)
Trial: 2206227
Drug: CyA monotherapy
RxNorm normalized name: CyA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA monotherapy (group B)
Trial: 2206227
Drug: Triple drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple drug treatment
Trial: 2206227
Drug: Aza and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aza and MP, CyA monotherapy, CyA and MP (controls)
Trial: 400933
Drug: Cefoxitin (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2.0 g intramuscularly with 1.0 g of oral probenecid)
Trial: 400933
Drug: Aqueous procaine
RxNorm normalized name: Aqueous procaine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous procaine penicillin G (4.8 x 10(6) units intramuscularly with 1.0 g of oral probenecid)
Trial: 15200541
Drug: Bupivacaine irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine irrigation through the axillary wound drain 4-hourly for 24 h postoperatively
Trial: 12047399
Drug: glyburide/metformin 1.25/250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glyburide/metformin 1.25/250 mg
Trial: 12047399
Drug: glyburide/metformin 2.5/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glyburide/metformin 2.5/500 mg
Trial: 12047399
Drug: glyburide/metformin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glyburide/metformin (both doses)
Trial: 2059756
Drug: Methotrexate (MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (MTX 10 mg/m2) given on days 1, 3, and 6, and daily cyclosporine (CSP) on days -1 through 180
Trial: 2059756
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of MTX and daily CSP
Trial: 6841304
Drug: Acyclovir, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir, 10 and 15 mg/kg 8 hourly, given as an iv bolus or iv infusion over 1 h for up to 7 days
Trial: 6841304
Drug: Acyclovir, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir, 10 and 15 mg/kg 8 hourly, given as an iv bolus
Trial: 6841304
Drug: Acyclovir, high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir, high dosage by iv bolus mode of administration
Trial: 6841304
Drug: Acyclovir, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir, 15 mg/kg 8‐hourly
Trial: 30058646
Drug: Oral CoQ10
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral CoQ10 supplementation
Trial: 26177791
Drug: Alendronate (ALN)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN) 70 mg weekly for 48 weeks
Trial: 26177791
Drug: Baseline 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline 25(OH)D < 32 ng/mL
Trial: 20150883
Drug: 1 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Hz real-rTMS of the SI cortex for 30 minutes daily for 5 days
Trial: 16188715
Drug: Psychotherapy (eight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy (eight sessions of cognitive behavioral therapy) plus pharmacotherapy (citalopram)
Trial: 12885836
Drug: Standard timing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard timing chemotherapy (DCTER: dexamethasone, cytarabine arabinoside, 6‐thioguanine, etoposide, daunorubicin)
Trial: 12885836
Drug: Standard timing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard timing chemotherapy (DCTER)
Trial: 8458774
Drug: Naloxone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (3 mg intravenous infusion)
Trial: 2429117
Drug: Clonidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (200 micrograms as a single dose)
Trial: 2429117
Drug: Chronic administration
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic administration of clonidine (200 micrograms twice a day for 3 weeks)
Trial: 2429117
Drug: Chronic administration
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic administration of clonidine (400 micrograms twice a day for 6 weeks)
Trial: 22751847
Drug: Fingolimod, 0.5
RxNorm normalized name: Fingolimod, 0.5 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod, 0.5 mg
Trial: 30439315
Drug: Comfort analgesic
RxNorm normalized name: Comfort Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comfort analgesic sedative scheme with immediate analgesia and sedation score, CPOT 0-1 and RASS -1-0.
Trial: 30439315
Drug: Daily analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily analgesic and sedation regimen with CPOT 0-3 and RASS maintained at -3 to -4.
Trial: 19945740
Drug: Six cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles of chemotherapy
Trial: 19945740
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of chemotherapy
Trial: 7200653
Drug: Topical instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical instillation of adriamycin
Trial: 27333382
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (15 mg/kg/day for 12 months)
Trial: 17720098
Drug: Gamma tocopherol
RxNorm normalized name: Gamma tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma tocopherol (308 mg) and DHA (800 mg)
Trial: 15161110
Drug: Protease supplementation
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease supplementation (two tablets containing 325 mg pancreatic enzymes, 75 mg trypsin, 50 mg papain, 50 mg bromelain, 10 mg amylase, 10 mg lipase, 10 mg lysozyme, 2 mg chymotrypsin) four times a day for 4 days starting 1 day before exercise
Trial: 11800415
Drug: Trimetazidine 20
RxNorm normalized name: trimetazidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 20 mg orally every 8 hours during hospitalization
Trial: 2610721
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 200 mg naftidrofuryl
Trial: 30647436
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg phospholipid curcumin, one capsule per day for 8 weeks
Trial: 29061728
Drug: Coupler implantation
RxNorm normalized name: Complera
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Coupler implantation and continuing previous pharmacotherapy
Trial: 29061728
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment alone
Trial: 26867335
Drug: Dual cycle
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual cycle and dual channel treatment (Group B)
Trial: 26867335
Drug: Conventional single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional single cycle treatment (Group A)
Trial: 21931204
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg, one tablet every 6 hours for three days
Trial: 12801493
Drug: Auricular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular therapy using magnetic pearls
Trial: 10826459
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg twice daily for 5 days followed by 400 mg twice daily for 5 days
Trial: 10826459
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily for 10 days
Trial: 2053097
Drug: Psoas compartment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psoas compartment block with additional inhalation anaesthesia
Trial: 17971587
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and RT during induction (up-front RT)
Trial: 15368110
Drug: Montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium (10 mg daily)
Trial: 15100671
Drug: Levocetirizine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine (5 mg)
Trial: 9519853
Drug: SAIB (sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAIB (sucrose acetate isobutyrate) ingestion at a dose of 20 mg/kg body weight for 14 days
Trial: 2801555
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy (placebo group)
Trial: 2801555
Drug: Proximal left
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proximal left anterior descending coronary artery affected (Anticoagulant therapy)
Trial: 822858
Drug: Thyrotrophin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotrophin-releasing hormone (TRH) injection
Trial: 822858
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid injection
Trial: 31604146
Drug: Dietary nitrate
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary nitrate supplementation (beetroot-based high-nitrate supplement)
Trial: 29137842
Drug: Cetrozole (1.98
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrozole (1.98 μg)
Trial: 29137842
Drug: TMD-322 (1.98
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMD-322 (1.98 μg)
Trial: 29137842
Drug: Anastrozole (1.98
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1.98 μg)
Trial: 22672214
Drug: Liquid paraffin
RxNorm normalized name: Liquid paraffin
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid paraffin plus antiseptic cream
Trial: 23219861
Drug: Pimozide augmentation
RxNorm normalized name: Pimozide
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimozide augmentation
Trial: 21642511
Drug: Low-dose PSW
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose PSW treatment (power of 14.5 W, treatment duration of 19 minutes, total energy of 17 kJ)
Trial: 21642511
Drug: High-dose PSW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose PSW treatment (power of 14.5 W, treatment duration of 38 minutes, total energy of 33 kJ)
Trial: 18804555
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg q.d.)
Trial: 17303443
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (capacitively coupled, pulsed electrical stimulation device)
Trial: 11236229
Drug: Combination gel
RxNorm normalized name: SUNSCREEN-30 PABA-FREE COMBINATION GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination gel (5% benzoyl peroxide and 1% clindamycin)
Trial: 2511136
Drug: vasopressin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vasopressin (0.4 to 0.8 unit per min for 12 hr) associated with transdermal nitroglycerin (10 mg in 24 hr)
Trial: 1015360
Drug: Sulfaisomidine administered
RxNorm normalized name: sulfisomidine
DrugBank: Sulfaisodimidine (DB13283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfaisomidine administered on an empty stomach
Trial: 1015360
Drug: Sulfaisomidine administered
RxNorm normalized name: sulfisomidine
DrugBank: Sulfaisodimidine (DB13283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfaisomidine administered with a standardized breakfast
Trial: 31519301
Drug: Capsaicin 8%
RxNorm normalized name: CAPSAICIN 8% PATCH KIT,4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin 8% cream (CPS)
Trial: 31519301
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (PLA)
Trial: 26658524
Drug: Task-oriented exercise
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-oriented exercise with mirror therapy (EG)
Trial: 24447460
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT) delivered by highly trained professional therapists
Trial: 24447460
Drug: Behavioural Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural Activation (BA) and Cognitive Behaviour Therapy (CBT)
Trial: 21058475
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection therapy with compound Danshen injection at Zusanli (ST 36) and Weishu (BL 21) for 2 weeks
Trial: 21058475
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Omeprazole for 2 weeks
Trial: 15637764
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with Fuzheng Yiliu decoction
Trial: 10454403
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of a standard smoking cessation programme with nicotine gum and a behavioural weight control programme including a very low energy diet
Trial: 8580269
Drug: GR122311X 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR122311X 200 mg b.d.
Trial: 8580269
Drug: GR122311X 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR122311X 400 mg b.d.
Trial: 8580269
Drug: GR122311X 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR122311X 800 mg b.d.
Trial: 8580269
Drug: Ranitidine hydrochloride
RxNorm normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine hydrochloride 150 mg b.d.
Trial: 2790864
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of zinc citrate (14.4 mM) and SLS (34.7 mM)
Trial: 31556633
Drug: Schema mindfulness-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schema mindfulness-based cognitive therapy (SMBCT) + treatment as usual (TAU)
Trial: 31556633
Drug: Competitive memory
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Competitive memory therapy (COMET) + treatment as usual (TAU)
Trial: 31171755
Drug: Eculizumab (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (monoclonal antibody against complement C5)
Trial: 28147351
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment (balloon dilatation and stenting)
Trial: 21288340
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention including a depression awareness and physical activity training session for care home staff, plus a whole home physical activation programme with twice weekly physiotherapist-led exercise groups for 12 months.